Want to see PLSE full AI Analyst Report?
PLSE Stock Chart & Stats
$30.23
$2.56(8.47%)
At close: 4:00 PM EDT
$30.23
$2.56(8.47%)
Day’s Range― - ―
52-Week Range$12.56 - $45.90
Previous Close$32.94
Volume432.45K
Average Volume (3M)189.63K
Market Cap
$2.43B
Enterprise Value$1.41K
Total Cash (Recent Filing)$101.62M
Total Debt (Recent Filing)$6.77M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 16, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding69,209,710
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.50Price Target Upside10.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$2.73M
Bulls Say, Bears Say
Bulls Say
Accelerated Pivotal EnrollmentRapid enrollment in the NANOPULSE‑AF pivotal trial materially shortens regulatory timelines and validates clinical interest. Sustained enrollment momentum reduces timeline risk for IDE/PMA modules, builds investigator buy‑in, and improves likelihood of a timely path to market authorization and commercial launch.
Positive EU Feasibility DataCompelling feasibility efficacy and safety signals in Europe strengthen the clinical value proposition of nsPFA, supporting broader adoption. Durable positive outcomes and low adverse events bolster physician confidence, reimbursement discussions, and clinic uptake across cardiology and surgical indications.
Improved Liquidity & Financing FlexibilityA strengthened balance sheet with over $100M and an additional $75M ATM facility extends runway and gives management optionality. This reduces near‑term insolvency risk, allows focused investment in pivotal trials and regulatory activities, and supports commercialization buildup without immediate distress financing.
Bears Say
Minimal Product RevenueCurrent commercial traction remains extremely limited, with product revenue at a de minimis level. This indicates the business is still pre‑commercial at scale, leaving execution risk around building recurring consumable sales, customer adoption, and establishing sustainable procedure volumes in clinics and ASCs.
High Cash BurnPersistent, large negative operating cash flow shows R&D and trial investment are translating to real cash outflows. Even with recent improvement, ongoing burn demands continued capital access; prolonged negative cash conversion impairs financial flexibility and could pressure strategic options absent sustained revenue ramp or lower spend.
Financing Dependence/dilution RiskThe company’s progress has been enabled by repeated equity raises and warrant exercises, signaling dependence on capital markets. Continued reliance increases dilution risk and may constrain long‑term shareholder alignment if frequent offerings are needed to fund pivotal trials and commercialization before meaningful product cash flow emerges.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $45.90 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $2.43B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 100 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.284 earnings per share for the quarter, beating the consensus estimate of -$0.293 by $0.009.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.31.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 69,209,710 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.284 in its last earnings report, beating expectations of -$0.293. Following the earnings report the stock price went up 10.905%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.50 (10.82% Upside)
$33.50 (10.82% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 31.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.81%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
PLSE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, positive clinical momentum and operational progress: accelerated pivotal enrollment, compelling EU feasibility efficacy and safety data, procedural efficiency that suggests meaningful hospital economics, strengthened leadership, and a materially improved cash position following ATM proceeds. These positives are balanced by early-stage commercial revenue that remains small, rising operating expenses and widening losses driven by increased clinical investment, ongoing cash burn, and continued dependence on capital markets. Regulatory timing still depends on 12-month follow-up for earlier enrollees, creating a measurable timeline risk. On balance, the highlights — particularly the rapid enrollment, robust feasibility outcomes, and strengthened balance sheet — outweigh the lowlights.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$33.50
▲(10.82% Upside)
Technical Analysis
Ownership Overview
73.02% Insiders
2.26% Mutual Funds
0.33% Other Institutional Investors
21.33% Public Companies and
Individual Investors